BTIG raised the firm’s price target on Zimmer Biomet (ZBH) to $123 from $122 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in the MedTech space.

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price target of $123.00. The company’s shares closed last ...

Alfred Bonati, the founder, chief surgeon and face of the the Bonati Spine Institute, has filed for Chapter 11 bankruptcy with debts of more than $10 million, court records show. Chapter 11 ...

Zimmer Biomet’s CEO, Ivan Tornos, earned $15 million in total compensation in 2024, according to a recent Securities and Exchange Commission proxy filing. The devicemaker’s March 29 filing revealed ...

PITTSBURGH — A Roberto Clemente logo at PNC Park was seemingly replaced with an advertisement. A post shared by Roberto Clemente Jr. shows the spot where his father’s logo was previously ...